Goldman Sachs’s Agile Therapeutics AGRX Stock Holding History

Goldman Sachs’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-20	Closed	-$108K	–	6497
2017 Q4	$108K	Buy	+20	New	+$186K	﹤0.01%	5714

Other funds holding AGRX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs's AGRX Position: Q1 2022 in Review

Goldman Sachs sold out of Agile Therapeutics (AGRX) in Q1 2022, closing a stake of 12 shares — an estimated $12K sold.

Goldman Sachs first reported a position in AGRX in Q2 2014 and held it in 14 quarters. The position peaked at $612K in Q3 2014. 36 funds tracked by Wall St. Rank hold AGRX as of Q1 2022.

Goldman Sachs reported no remaining Agile Therapeutics position as of Q1 2022 after selling out during the quarter.
Goldman Sachs sold 12 Agile Therapeutics shares in Q1 2022, an estimated $12K.
Goldman Sachs first reported a position in Agile Therapeutics in Q2 2014 and held it in 14 quarters.
Goldman Sachs's Agile Therapeutics position peaked at $612K in Q3 2014.
36 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2022.

Based on Goldman Sachs's 13F filing for Q1 2022, filed 16 May 2022.